Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences2018-01-17T17:02:55-05:00
Cost of Managing an Episode of Relapse in Multiple Sclerosis in the United States Cost of Managing an Episode of Relapse in Multiple Sclerosis in the United States2018-01-17T17:02:55-05:00
Marijuana as a treatment for epilepsy and multiple sclerosis? Marijuana as a treatment for epilepsy and multiple sclerosis?2018-01-17T17:02:49-05:00
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis2018-01-17T17:02:43-05:00
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis2018-01-17T17:02:43-05:00
COX-2 Inhibitors — A Lesson in Unexpected Problems COX-2 Inhibitors — A Lesson in Unexpected Problems2018-01-17T17:02:37-05:00
Daclizumab Zenapax inhibits early interleukin-2 receptor / signal transduction events Daclizumab Zenapax inhibits early interleukin-2 receptor / signal transduction events2018-01-17T17:02:37-05:00